Prevail InfoWorks’ Post

Complement 3 glomerulopathy (C3G) poses a significant burden on affected individuals, healthcare systems, and society at large due to its complex pathophysiology and challenging treatment landscape. As per DelveInsight Business Research LLP, the overall diagnosed prevalent population of C3G in the 7MM was reported as ~5.7K in 2023 and the cases are anticipated to increase by 2032. With the continued collaboration, investment, and dedication of the pharma giants such as Apellis Pharmaceuticals (pegcetacoplan), and Novartis (iptacopan), Amyndas Pharmaceuticals (AMY-101), Arrowhead Pharmaceuticals (ARO-C3) and others, the C3G therapeutics market is set to evolve immensely in the upcoming years. Get a detailed analysis of the evolving C3G therapeutics market, at: https://lnkd.in/gt9Rwr5A #healthcare #biotechnology #lifesciences #pharmaceuticalindustry #pharmaceutical #marketresearch #marketforecast #markettrends #consulting #healthcareconsulting #consultingservices #marketforecast

Altimmune, Inc., a clinical-stage biopharmaceutical company focused on the development of novel peptide-based therapeutics for the treatment of obesity and liver diseases, announced ‘…results from its 48-week MOMENTUM Phase 2 obesity trial of pemvidutide…’, a GLP-1/glucagon dual receptor agonist. From almost 400 patients, with a mean BMI of 37 of whom three-quarters were female, some achieved mean weight losses of up to 15.6%, primarily those on the highest 2.4mg dose, at week 48, with 30% of those achieving 20% in weight loss. One in four patients on the drug did not complete the trial, though the ‘…majority of adverse events were predominantly mild to moderate in severity.’ Dr. M. Scott Harris, Chief Medical Officer of Altimmune said ‘…the trajectory of weight loss at the end of treatment with the 2.4 mg dose suggests the potential for greater weight loss with continued treatment.’ CEO Dr. Vipin Garg added ‘…This is an important day for Altimmune and we couldn’t be more pleased with these results…’ which was supported by investors with a hike in their stock price of 40%. https://lnkd.in/eSMCDwb3

𝗘𝗳𝗳𝗲𝗰𝘁𝘀 𝗼𝗳 𝘀𝗲𝗺𝗮𝗴𝗹𝘂𝘁𝗶𝗱𝗲-𝗹𝗼𝗮𝗱𝗲𝗱 𝗹𝗶𝗽𝗶𝗱 𝗻𝗮𝗻𝗼𝗰𝗮𝗽𝘀𝘂𝗹𝗲𝘀 𝗼𝗻 𝗺𝗲𝘁𝗮𝗯𝗼𝗹𝗶𝗰 𝗱𝘆𝘀𝗳𝘂𝗻𝗰𝘁𝗶𝗼𝗻-𝗮𝘀𝘀𝗼𝗰𝗶𝗮𝘁𝗲𝗱 𝘀𝘁𝗲𝗮𝘁𝗼𝘁𝗶𝗰 𝗹𝗶𝘃𝗲𝗿 𝗱𝗶𝘀𝗲𝗮𝘀𝗲 Metabolic dysfunction-associated steatotic liver disease (MASLD) is a highly prevalent chronic liver disease that can progress to end-stage conditions with life-threatening complications, but no pharmacologic therapy has been approved. Drug delivery systems such as lipid nanocapsules (LNC) are very versatile platforms that are easy to produce and can induce the secretion of the native glucagon-like peptide 1 (GLP-1) when orally administered. GLP-1 analogs are currently being studied in clinical trials in the context of MASLD. Our nanosystem provides with increased levels of the native GLP-1 and increased plasmatic absorption of the encapsulated GLP-1 analog (semaglutide). Read more in the article. #pharmaceutical #lipid #nanocapsules

Sanofi’s Lixisenatide, a 44 amino acid peptide and a GLP-1 agonist (same family as Novo Nordisk’s Semaglutide and Eli Lilly’s Tirzepatide), has shown some efficacy to halt Parkinson’s disease progression during a phase II clinical trial. GLP-1 agonists are a blockbuster drug family, with demonstrated effects against diabetes and obesity. GLP-1 agonists not only lead to weight loss but it was also demonstrated that they reduce obesity associated symptoms such as heart failure and the risk of heart attacks and strokes. This family is expected to reduce inflammation leading to neuron loss and is being tested during clinical trials for Parkinson’s and Alzheimer’s diseases. 💡 https://lnkd.in/dQhjXeEm 🔬 https://lnkd.in/dzUeZVH3 #Drugdevelopment #Pharmaceuticals #Parkinson

🚀 So what comes next? After yesterday's announcement by the FDA that #Rezdiffra (formerly known as #resmetirom, by Madrigal Pharmaceuticals) has become the first FDA-approved drug for the treatment of adults with non-cirrhotic #NASH (#MASH), I have so many questions: 1/ Given that prescribing does not include #liverbiopsy, how will the patients be eligible for this #therapy and for #reimbursement? 2/ How will patients be prioritized for therapeutic intervention? 3/ How will this announcement change the clinical trial landscape? Will current clinical trials have to open a new arm with resmetirom-treated patients, with the numerous companies already engaged or about to engage in Phase 3 (Inventiva Pharma and #lanifibranor, Novo Nordisk and #semaglutide, Boehringer Ingelheim and #survodutide, Akero Therapeutics and #efruxifermin, 89bio and #BIO89-100, Terns Pharmaceuticals and #TERN-101) 4/ What is the future of #liverbiopsy in the enrolment of patients in clinical trials, given that #NITs are not yet ready-to-use for both #diagnosis and patient's #monitoring? Please, I'll be happy to hear your thoughts and to have an open debate on these questions, of which the answers will be important to the understanding of the future. Put the question number and your answer in the comments!

SGLT-2 inhibitors . Last updated on May 30, 2023. Other names: sodium-glucose cotransporter-2 inhibitors What are SGLT-2 inhibitors? SGLT-2 inhibitor is an abbreviation for sodium-glucose cotransporter-2 inhibitors. SGLT-2 inhibitors are a class of medicine used to lower high blood glucose levels in people with type 2 diabetes. They may also be called gliflozins. SGLT-2 inhibitors inhibit SGLT-2 proteins located in the renal tubules of the kidneys which are responsible for reabsorbing glucose back into the blood. As a result, more glucose is excreted in the urine. SGLT-2 inhibitors have been shown to be effective at lowering hemoglobin A1c levels, improving weight loss and lowering blood pressure. They carry a low risk of hypoglycemia (low blood sugar levels). They are usually well tolerated. SGLT-2 inhibitors may be used in the treatment of type 2 diabetes and act independently of beta-cell function in the pancreas. List of SGLT-2 inhibitors View by Brand | Generic Filter by   All conditions   Cardiovascular Risk Reduction   Chronic Kidney Disease   Diabetes, Type 2   Diabetic Kidney Disease   Heart Failure   Drug Name Avg. Rating Reviews Jardiance (Pro) Generic name: empagliflozin Generic name: canagliflozin5.8 Farxiga (Pro) Generic name: dapagliflozin4.7 Steglatro (Pro) Generic name: ertugliflozin5.8 Brenzavvy (Pro) Generic name: bexagliflozin10 See also Medical conditions treated or associated with SGLT-2 inhibitors: Cardiovascular Risk Reduction Chronic Kidney Disease Diabetes, Type 2 Diabetic Kidney Disease Heart Failure

GLP-1 receptor agonists have made waves in the #pharmaceutical industry over the past few years for their treatment of type 2 #diabetes and #obesity. With #semaglutide, exenatide, and other GLP-1s emerging as some of the most popular #prescription drugs in the US, researchers are exploring the scope of these drugs for other conditions such as cardiovascular #disease, #alcohol use disorder, smoking cessation, and more. https://lnkd.in/eKg3re5N

In case you have missed it, here is the #published article on our #Pharmaceuticals 🤩 Targeted Treatment against #Lipoprotein (a): The Coming Breakthrough in #Lipid Lowering Therapy by Sosnowska et al. Enjoy reading: https://brnw.ch/21wL7Jf

Semaglutide appears to be efficacious in the secondary prevention of cardiovascular disease for people without diabetes. 💉 Need to see the full trial to determine what drove the reduction in MACE and review the safety profile. It will be interesting to see whether these benefits extend to primary prevention. There is an ongoing trial of tirzepatide that will answer this question. Meanwhile Novo Nordisk is now worth more than the entire economy of its native Denmark. There will be challenges to ensure the quality use of GLP1RAs in this space. #Obesity #Pharmaceuticals #Semaglutide

🤔 The global diabetes pandemic has created a massive demand for insulin, but affordability has continued to be a significant barrier for patients to obtain this lifesaving drug. One of the most expensive steps in manufacturing insulin therapeutics is during the purification process. 🎯 A cost-effective approach to improve peptide purification efficiency is to add an orthogonal upstream separation step. Read how this approach can reduce the cost of insulin here 👉: https://lnkd.in/dne8hvRR #biopharmaceuticals #peptides #upstreamprocessing #chromatography #purification